Profound Medical Corp. is set to launch its TULSA-AI Volume Reduction module for treating benign prostatic hyperplasia (BPH) at the RSNA meeting.
The TULSA Procedure™, utilizing Profound's TULSA-PRO ® system, offers an incision-free solution for prostate diseases.
The company will also unveil new data on TULSA-PRO for prostate cancer at the RSNA and SUO meetings.
AI-Powered BPH Module Launch
Introduction of TULSA-AI Volume Reduction module to optimize BPH treatment procedures.
Clinical Data Presentation
Showcasing real-world data evidencing reduced risk of complications and superior outcomes of the TULSA Procedure compared to traditional methods.
Market Expansion Projection
Expectation to triple the total available market in prostate disease to about 600,000 patients annually with the new AI module.
- The TULSA Procedure's clinical flexibility and advanced benefits are driving demand from patients and healthcare providers.
- The use of AI in the TULSA-AI Volume Reduction module is expected to streamline workflow and reduce procedural times significantly.
- New data presentation at RSNA and SUO events highlights the effectiveness and potential of TULSA-PRO in prostate disease management.
Profound Medical's innovative approach in utilizing AI for BPH treatment presents a promising advancement in prostate healthcare, potentially transforming the treatment landscape.